(2-phenylacetyl)urea

• ChemBase ID: 992
• Molecular Formular: C9H10N2O2
• Molecular Mass: 178.1879
• Monoisotopic Mass: 178.07422757
• SMILES: O=C(NC(=O)N)Cc1ccccc1
• Canonical SMILES: O=C(Cc1ccccc1)NC(=O)N
• InChI: InChI=1S/C9H10N2O2/c10-9(13)11-8(12)6-7-4-2-1-3-5-7/h1-5H,6H2,(H3,10,11,12,13)
• InChIKey: XPFRXWCVYUEORT-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: (2-phenylacetyl)urea
• IUPAC Traditional name: phenacemide
• Brand Name: Acetylureum; Carbanmide; Cetylureum; Comitiadone; Eferon; Efron; Epheron; Epiclase; Felurea; Fenacemid; Fenacemide; Fenacetamide; Fenacetil-Karbamide; Fenilep; Fenised; Fenostenyl; Fenural; Fenurea; Fenurone; Fenylacetylmocovina; Fenytan; Neophedan; Neophenal; Phacetur; Phenacalum; Phenacereum; Phenacetur; Phenarone; Phenicarb; Phenuron; Phenurone; Phenutal; Phenyrit; Phetylureum
• Synonyms: Phenylacetylurea; Phenylacetylurea; Phenylacetyluree; Phenacemide; Carbamide phenylacetate; PA; Phenacetylcarbamide; Phenacetylurea; sym-ACETYLPHENYL UREA; 苯乙酰脲

Database IDs

• CAS Number: 63-98-9
• EC Number: 200-570-2
• MDL Number: MFCD00007948
• PubChem SID: 160964455; 46508400
• PubChem CID: 4753
• ATC CODE: N03AX07
• CHEMBL: 918
• Chemspider ID: 4589
• DrugBank ID: DB01121
• KEGG ID: D00504
• Unique Ingredient Identifier: PAI7J52V09
• Wikipedia Title: Phenacemide

CALCULATED PROPERTIES

JChem

• Acid pKa: 11.746752
• H Acceptors: 2
• H Donor: 2
• LogD (pH = 5.5): 0.45911402
• LogD (pH = 7.4): 0.45909494
• Log P: 0.45911425
• Molar Refractivity: 47.4304 cm^3
• Polarizability: 18.282602 Å^3
• Polar Surface Area: 72.19 Å^2
• Rotatable Bonds: 2
• Lipinski's Rule of Five: true

ALOGPS 2.1

• Log P: 0.81
• LOG S: -2.23
• Solubility (Water): 1.06e+00 g/l

PROPERTIES

Physical Property

• Solubility: 10.2 g/L
• Hydrophobicity(logP): 0.8

Safety Information

• RTECS: YU0875000
• European Hazard Symbols: Harmful (Xn)
• German water hazard class: 2
• Risk Statements: 22
• GHS Pictograms: GHS07
• GHS Signal Word: Warning
• GHS Hazard statements: H302
• Personal Protective Equipment: dust mask type N95 (US), Eyeshields, Gloves

Pharmacology Properties

• Half Life: 22-25 hours.

Product Information

• Purity: 98%
• Empirical Formula (Hill Notation): C9H10N2O2

DETAILS

MP Biomedicals - 05206423

MP Biomedicals Rare Chemical collection

DrugBank - DB01121

• Drug Groups: approved
• Description: Phenacemide is used to control certain seizures in the treatment of epilepsy. This medicine acts on the central nervous system (CNS) to reduce the number and severity of seizures.
• Indication: Used to control certain seizures in the treatment of epilepsy.
• Pharmacology: Phenacemide is a ureal anticonvulsant indicated for control of severe epilepsy, particularly mixed forms of complex partial (psychomotor or temporal lobe) seizures, refractory to other anticonvulsants. Phenacemide elevates the threshold for minimal electroshock convulsions and abolishes the tonic phase of maximal electroshock seizures. It also prevents or modifies seizures induced by pentylenetetrazol or other convulsants.
• Toxicity: Oral, mouse: LD₅₀ = 987 mg/kg; Oral, rabbit: LD₅₀ = 2500 mg/kg; Oral, rat: LD₅₀ = 1600 mg/kg
• Affected Organisms: Humans and other mammals
• Biotransformation: Metabolized in the liver by hepatic microsomal enzymes, where it is inactivated by p-hydroxylation.
• Absorption: Almost completely absorbed.
• Half Life: 22-25 hours.
• References: Coker SB: The use of phenacemide for intractable partial complex epilepsy in children. Pediatr Neurol. 1986 Jul-Aug;2(4):230-2. [Pubmed] ; Coker SB, Holmes EW, Egel RT: Phenacemide therapy of complex partial epilepsy in children: determination of plasma drug concentrations. Neurology. 1987 Dec;37(12):1861-6. [Pubmed]
• External Links: Wikipedia

REFERENCES

• Coker SB: The use of phenacemide for intractable partial complex epilepsy in children. Pediatr Neurol. 1986 Jul-Aug;2(4):230-2. Pubmed
• Coker SB, Holmes EW, Egel RT: Phenacemide therapy of complex partial epilepsy in children: determination of plasma drug concentrations. Neurology. 1987 Dec;37(12):1861-6. Pubmed